Here's Why Shareholders Will Not Be Complaining About Ascentage Pharma Group International's (HKG:6855) CEO Pay Packet
May 12
Have your own idea? Try our Stock Screener
Hong Kong (HSI) Biotech Industry Analysis
UpdatedMay 15, 2025
DataAggregated Company Financials
Companies52
- 7D-1.5%
- 3M45.1%
- 1Y39.9%
- YTDn/a
In the last week, the Biotech industry is down 5.9% with Innovent Biologics down the most at 10%. In contrast, HighTide Therapeutics has gained 73%. In the past year, the industry has gained 40%. Looking forward, earnings are forecast to grow by 44% annually.
Industry Valuation and Performance
Has the Hong Kong Biotech Industry valuation changed over the past few years?
| Date | Market Cap | Revenue | Earnings | PE | Absolute PE | PS |
|---|---|---|---|---|---|---|
| Thu, 15 May 2025 | HK$553.0b | HK$61.6b | -HK$11,837,331,364.97 | 29.2x | -46.7x | 9x |
| Sat, 12 Apr 2025 | HK$501.4b | HK$58.1b | -HK$10,821,518,059.10 | 26.3x | -46.3x | 8.6x |
| Mon, 10 Mar 2025 | HK$461.2b | HK$52.5b | -HK$16,893,132,103.38 | 22.7x | -27.3x | 8.8x |
| Wed, 05 Feb 2025 | HK$358.8b | HK$52.3b | -HK$17,392,018,984.26 | 12.6x | -20.6x | 6.9x |
| Fri, 03 Jan 2025 | HK$367.2b | HK$51.9b | -HK$17,241,784,830.06 | 10.8x | -21.3x | 7.1x |
| Sun, 01 Dec 2024 | HK$399.6b | HK$52.3b | -HK$17,390,148,785.72 | 10.7x | -23x | 7.6x |
| Tue, 29 Oct 2024 | HK$392.5b | HK$52.3b | -HK$17,891,036,991.36 | 11.4x | -21.9x | 7.5x |
| Thu, 26 Sep 2024 | HK$355.1b | HK$53.0b | -HK$18,425,985,001.97 | 11x | -19.3x | 6.7x |
| Sat, 24 Aug 2024 | HK$332.2b | HK$53.4b | -HK$18,895,611,066.02 | 11x | -17.6x | 6.2x |
| Mon, 22 Jul 2024 | HK$324.3b | HK$49.6b | -HK$19,438,335,694.28 | 12.6x | -16.7x | 6.5x |
| Wed, 19 Jun 2024 | HK$338.1b | HK$49.7b | -HK$19,469,839,436.05 | 10.5x | -17.4x | 6.8x |
| Fri, 17 May 2024 | HK$371.5b | HK$49.9b | -HK$19,423,587,854.26 | 12.1x | -19.1x | 7.4x |
| Sun, 14 Apr 2024 | HK$341.5b | HK$49.6b | -HK$19,926,257,322.48 | 11x | -17.1x | 6.9x |
| Tue, 12 Mar 2024 | HK$345.7b | HK$47.3b | -HK$20,415,595,754.97 | 16.5x | -16.9x | 7.3x |
| Thu, 08 Feb 2024 | HK$321.9b | HK$47.2b | -HK$20,396,378,333.69 | 15.5x | -15.8x | 6.8x |
| Sat, 06 Jan 2024 | HK$376.6b | HK$47.1b | -HK$20,327,490,552.00 | 16.9x | -18.5x | 8x |
| Mon, 04 Dec 2023 | HK$427.8b | HK$47.0b | -HK$20,310,389,111.00 | 18.9x | -21.1x | 9.1x |
| Wed, 01 Nov 2023 | HK$413.5b | HK$45.0b | -HK$18,757,275,840.00 | 13.2x | -22x | 9.2x |
| Fri, 29 Sep 2023 | HK$408.6b | HK$44.9b | -HK$19,123,315,931.00 | 14.3x | -21.4x | 9.1x |
| Sun, 27 Aug 2023 | HK$373.5b | HK$39.2b | -HK$20,093,496,287.00 | 15.7x | -18.6x | 9.5x |
| Tue, 25 Jul 2023 | HK$400.4b | HK$35.4b | -HK$23,308,003,844.00 | 26x | -17.2x | 11.3x |
| Thu, 22 Jun 2023 | HK$396.9b | HK$35.5b | -HK$23,362,967,980.00 | 24.5x | -17x | 11.2x |
| Sat, 20 May 2023 | HK$427.4b | HK$36.2b | -HK$23,905,842,911.00 | 31x | -17.9x | 11.8x |
| Mon, 17 Apr 2023 | HK$469.8b | HK$37.1b | -HK$24,226,204,473.00 | 18.7x | -19.4x | 12.7x |
| Wed, 15 Mar 2023 | HK$388.0b | HK$33.2b | -HK$36,421,384,339.00 | 21.2x | -10.7x | 11.7x |
| Fri, 10 Feb 2023 | HK$450.6b | HK$35.0b | -HK$35,367,953,982.00 | 29.8x | -12.7x | 12.9x |
| Sun, 08 Jan 2023 | HK$426.7b | HK$34.6b | -HK$34,879,667,099.00 | 30.9x | -12.2x | 12.3x |
| Tue, 06 Dec 2022 | HK$363.6b | HK$33.4b | -HK$33,663,153,817.00 | 23.3x | -10.8x | 10.9x |
| Thu, 03 Nov 2022 | HK$347.8b | HK$33.4b | -HK$32,116,950,613.00 | 18.6x | -10.8x | 10.4x |
| Sat, 01 Oct 2022 | HK$286.1b | HK$34.0b | -HK$32,506,419,134.00 | 17.1x | -8.8x | 8.4x |
| Mon, 29 Aug 2022 | HK$336.6b | HK$33.6b | -HK$37,916,598,169.00 | 11.9x | -8.9x | 10x |
| Wed, 27 Jul 2022 | HK$343.8b | HK$32.9b | -HK$46,314,226,342.00 | 13.5x | -7.4x | 10.5x |
| Fri, 24 Jun 2022 | HK$363.3b | HK$33.1b | -HK$46,647,965,449.00 | 14.3x | -7.8x | 11x |
| Sun, 22 May 2022 | HK$352.6b | HK$34.1b | -HK$45,992,673,559.00 | 14.1x | -7.7x | 10.3x |
Price to Earnings Ratio
-7.7x
Current Industry PE
- Investors are relatively neutral on the Hong Kong Biotechnology industry at the moment, indicating that they anticipate long term growth rates to remain steady.
- The industry is trading close to its 3-year average PS ratio of 9.1x.
Past Earnings Growth
- The earnings for companies in the Biotechnology industry have improved over the last three years.
- Revenues for these companies have grown 22% per year.
- This means that more sales are being generated by these companies overall, and subsequently losses are decreasing too.
Industry Comparison
How does Hong Kong Biotech compare with similar industries?
| HK Market | 3.79% | |
| Healthcare | 0.16% | |
| Biotech | -1.49% | |
| Biotech | -1.49% | |
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.
Top Stock Gainers and Losers
Which companies have driven the market over the last 7 days?
| Company | Last Price | 7D | 1Y | Valuation | |
|---|---|---|---|---|---|
| 2696 Shanghai Henlius Biotech | HK$40.00 | 12.7% +HK$2.4b | 119.8% | PE24.5x | |
| 2171 CARsgen Therapeutics Holdings | HK$19.28 | 24.5% +HK$2.1b | 216.1% | PS248.5x | |
| 9995 RemeGen | HK$41.20 | 6.2% +HK$1.3b | 26.2% | PS10.7x | |
| 2142 HBM Holdings | HK$9.27 | 9.8% +HK$653.3m | 562.1% | PE341.7x | |
| 1167 Jacobio Pharmaceuticals Group | HK$4.40 | 20.9% +HK$599.4m | 137.8% | PS20.6x |
